← board
LGND
distress 0/10 · well-funded / low risk$300.89-1%today-7% from 52w high
Revenue
$52M
Liquidity
$779M
Runway
—
Shares 1y
+2%
Price & events
+47.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
+1.5%
1W
+7.7%
1M
+31.7%
3M
+49.6%
6M
+120.9%
1Y
+193.9%
2Y
+295.3%
5Y
+377.2%
All
Overview
- Market Cap
- $6.03B
- Volume
- 34.50K
- 52 Week Range
- $122 – $323
- Total Shares
- 20.04M
- Float Shares
- 19.53M
- Short %
- 12.68%
- % Held by Insiders
- 2.37%
- % Held by Institutions
- 107.18%
- RVOL
- 0.07x
- Beta
- 0.98
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2026-08-06earningsEarningsEarnings releaseyahoo
- 2025-12-18partnershipPrivate placement investment in Athira Pharma, Inc.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 20,041,061 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $311 (+3% upside) · 10 analysts
- 2026-07-15RBC CapitalOutperform
- 2026-07-09B of A SecuritiesBuy
- 2026-07-08StifelBuy
- 2026-05-08RBC CapitalOutperform
- 2026-04-30HC Wainwright & Co.Buy
- 2026-04-28RBC CapitalOutperform
Competitors
- none identified
Recent news
- 2026-07-23Ligand Sets Aug. 6 Webcast for Second-Quarter Results - Stock Titan
- 2026-07-22Citi Initiates Buy Rating on Ligand Pharmaceuticals (LGND) Follo - GuruFocus
- 2026-07-21LGND Reinstated by Citigroup -- Price Target Announced at $387 - GuruFocus
- 2026-07-21Citi Initiates Buy Rating on Ligand Pharmaceuticals (LGND) Follo - GuruFocus
- 2026-07-21LGND Reinstated by Citigroup -- Price Target Announced at $387 - GuruFocus
- 2026-07-21Ligand (LGND) Receives Buy Rating with $387 Target from Citi - GuruFocus
- 2026-07-21Ligand (LGND) Receives Buy Rating with $387 Target from Citi - GuruFocus
- 2026-07-18Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Report - Results, Call & Slides - TipRanks
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.